BPMC Blueprint Medicines Corp

$129.46

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 8/18/2025

About Blueprint Medicines Corp

Blueprint Medicines Corporation, a precision therapy company, develops drugs for people with cancer and blood disorders, and multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy in the United States and Europe. The company is headquartered in Cambridge, Massachusetts.

Website: https://www.blueprintmedicines.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1597264
Address
45 SIDNEY STREET, CAMBRIDGE, MA, US
Valuation
Market Cap
$5.41B
P/E Ratio
nan
PEG Ratio
0.00
Price to Book
18.12
Performance
EPS
$-1.07
Dividend Yield
—
Profit Margin
-13.20%
ROE
-31.30%
Technicals
50D MA
$90.21
200D MA
$95.21
52W High
$121.90
52W Low
$73.04
Fundamentals
Shares Outstanding
64M
Target Price
$124.90
Beta
0.75

BPMC EPS Estimates vs Actual

● Estimated
● Actual

BPMC News & Sentiment

Jul 31, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Sanofi Q2 Earnings & Sales Miss, 2025 Top-Line View Raised, Stock Down
SNY misses Q2 earnings and sales estimates but lifts 2025 sales outlook on strong Dupixent and vaccine momentum.
Jul 22, 2025 • Benzinga SOMEWHAT-BULLISH
Sanofi Expands Respiratory Vaccine Portfolio With UK Biotech Buy - Sanofi ( NASDAQ:SNY )
Sanofi to pay $1.15 billion upfront for Vicebio, with up to $450 million in milestone payments. Vicebio's VXB-241 RSV-hMPV combo vaccine is in Phase 1 trials in older adults. A new wave of value and momentum stocks could be setting up for major moves-and Tim Melvin will name them live this ...
Jul 18, 2025 • Benzinga NEUTRAL
Press Release: Sanofi completes acquisition of Blueprint Medicines
Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025.
Jul 18, 2025 • GlobeNewswire NEUTRAL
Press Release: Sanofi completes acquisition of Blueprint Medicines
Sanofi completes acquisition of Blueprint Medicines ...
Jul 17, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Press Release: Sanofi announces extension of Blueprint tender offer
Sanofi announces extension of Blueprint tender offer ...
Jul 17, 2025 • Benzinga SOMEWHAT-BULLISH
Press Release: Sanofi announces extension of Blueprint tender offer
Sanofi announces extension of Blueprint tender offer Paris, July 17, 2025.
Sentiment Snapshot

Average Sentiment Score:

0.145
50 articles with scored sentiment

Overall Sentiment:

Neutral

BPMC Reported Earnings

Apr 30, 2025
Mar 31, 2025 (Pre market)
0.0 Surprise
  • Reported EPS: $0.00
  • Estimate: $-1.66
  • Whisper: —
  • Surprise %: 0.0%
Feb 13, 2025
Dec 31, 2024 (Pre market)
-0.08 Surprise
  • Reported EPS: $-0.79
  • Estimate: $-0.71
  • Whisper: —
  • Surprise %: -10.6%
Oct 30, 2024
Sep 30, 2024 (Pre market)
0.08 Surprise
  • Reported EPS: $-0.89
  • Estimate: $-0.97
  • Whisper: —
  • Surprise %: 8.2%
Aug 01, 2024
Jun 30, 2024 (Pre market)
0.49 Surprise
  • Reported EPS: $-0.80
  • Estimate: $-1.29
  • Whisper: —
  • Surprise %: 38.0%
May 02, 2024
Mar 31, 2024 (Pre market)
3.06 Surprise
  • Reported EPS: $1.40
  • Estimate: $-1.66
  • Whisper: —
  • Surprise %: 184.3%
Feb 15, 2024
Dec 31, 2023 (Pre market)
0.22 Surprise
  • Reported EPS: $-1.82
  • Estimate: $-2.04
  • Whisper: —
  • Surprise %: 10.8%
Oct 26, 2023
Sep 30, 2023 (Pre market)
0.17 Surprise
  • Reported EPS: $-2.20
  • Estimate: $-2.37
  • Whisper: —
  • Surprise %: 7.2%
Aug 02, 2023
Jun 30, 2023 (Pre market)
0.35 Surprise
  • Reported EPS: $-2.19
  • Estimate: $-2.54
  • Whisper: —
  • Surprise %: 13.8%
May 04, 2023
Mar 31, 2023 (Pre market)
0.52 Surprise
  • Reported EPS: $-2.15
  • Estimate: $-2.67
  • Whisper: —
  • Surprise %: 19.5%

Financials